Palla P, Vatteroni M L, Vacri L, Maggi F, Baicchi U
Blood Center and NAT Section, Azienda Ospedaliera-Universitaria, Pisa, Italy.
Vox Sang. 2006 Jan;90(1):59-62. doi: 10.1111/j.1423-0410.2005.00716.x.
The introduction of nucleic acid amplification technology (NAT) for screening pooled or individual donations remarkably improved the safety of blood products. The size of mini-pooled NAT is considered critical for identification of HIV-1 infected donors during preseroconversion phase of infection. We describe a case of HIV-1 infection in a serologically negative repeat blood donor identified by 16 minipool (MP) NAT.
The donation was tested by Roche Cobas AmpliScreen HIV-1 Test with manual extraction (MultiPrep Specimen Processing Procedure). The sensitivity of different MP sizes was observed. Serial samples of infected donor were examined with different third and fourth generation HIV-1 serological assays.
In the index donation viral load was 515 copies/ml corresponding to about 50 IU when diluted in 16 MP. Abbott third and fourth generation EIA tests detected the seroconversion four days later the index donation.
The report emphasizes the relevance of a very small size of MP to really reduce the window serologic phase of current EIA test by HIV-1 NAT test.
核酸扩增技术(NAT)用于筛查混合或个体献血显著提高了血液制品的安全性。在感染的血清转化前期,微型混合NAT的规模被认为对于识别HIV-1感染供体至关重要。我们描述了1例通过16个微型混合(MP)NAT检测出的血清学阴性的重复献血者感染HIV-1的病例。
采用罗氏Cobas AmpliScreen HIV-1检测试剂盒并通过手工提取(MultiPrep样本处理程序)对献血进行检测。观察了不同MP规模的敏感性。使用不同的第三代和第四代HIV-1血清学检测方法对受感染供体的系列样本进行检测。
在索引献血中,病毒载量为515拷贝/毫升,当在16个MP中稀释时相当于约50国际单位。雅培第三代和第四代酶免疫分析检测在索引献血4天后检测到血清转化。
该报告强调了极小规模的MP对于通过HIV-1 NAT检测真正缩短当前酶免疫分析检测的血清学窗口期的重要性。